期刊文献+

卡瑞利珠单抗联合化疗对老年肺癌患者的疗效及生存情况的影响

Effect of Carituzumab Monoclonal Antibody Combined with Chemotherapy on Efficacy and Survival in Elderly Patients with Lung Cancer
下载PDF
导出
摘要 【目的】探讨卡瑞利珠单抗联合化疗对老年肺癌患者3年生存率的影响。【方法】选取本院收治的80例肺癌老年患者,随机分为两组,每组40例。对照组患者进行常规化疗,观察组患者在化疗的基础上行卡瑞利珠单抗治疗。比较两组患者临床疗效及治疗前后血清T淋巴细胞亚群水平、卡氏生存质量(KPS)评分;比较两组患者不良发应发生率及3年的生存情况。【结果】观察组患者客观有效率为55.00%(22/40),显著高于对照组的32.50%(13/40)(P<0.05);两组患者疾病控制率比较,差异无统计学意义(P>0.05)。两组患者治疗后CD4^(+)、CD4^(+)/CD8^(+)水平较治疗前均升高,CD8^(+)则降低(P<0.05);治疗后,观察组CD4^(+)、CD4^(+)/CD8^(+)水平高于对照组,CD8^(+)则低于对照组(P<0.05)。治疗后,两组患者KPS评分高于同组治疗前(P<0.05),且观察组高于对照组(P<0.05)。两组患者不良反应总发生率比较,差异无统计学意义(P>0.05)。3年随访期间,观察组失访8例,死亡23例,存活9例;对照组失访6例,死亡28例,存活6例。Kaplan-Meier生存分析显示,两组存活率比较,差异无统计学意义(P>0.05)。【结论】卡瑞利珠单抗联合化疗较单一化疗方案治疗老年肺癌患者疗效显著,可提高患者免疫功能,且安全可靠。 【Objective】This study aimed to investigate the impact of carituzumab monoclonal antibody combined with chemotherapy on the three-year survival time in elderly patients with lung cancer.【Methods】Eighty elderly patients with lung cancer admitted to our hospital were randomly divided into two groups,with 40 patients in each group.The control group received conventional chemotherapy,while the observation group received carituzumab monoclonal antibody treatment on the basis of chemotherapy.The clinical efficacy,serum T lymphocyte subsets levels before and after treatment,Karnofsky performance status(KPS)score,adverse event incidence,and three-year survival were compared between the two groups.【Results】The objective response rate in the observation group was 55.00%(22/40),which was significantly higher than that in the control group 32.50%(13/40)(P<0.05).There was no significant difference in disease control rate between the two groups(P>0.05).After treatment,the levels of CD4^(+)and CD4^(+)/CD8^(+)in both groups increased,while CD8^(+)decreased compared to before treatment(P<0.05).after treatment,the levels of CD4^(+)and CD4^(+)/CD8^(+)in the observation group were higher than those in the control group,while CD8^(+)of the observation group was lower that of the control group(P<0.05).The KPS scores of both groups after treatment was higher than those before treatment(P<0.05);And the observation group had a higher KPS score than the control group(P<0.05).There was no significant difference in the overall incidence of adverse reactions between the two groups(P>0.05).During the 3-year follow-up period,8 patients were lost to follow-up in the observation group,while there were 23 deaths and 9 survivors.Meanwhile,in the control group,6 patients were lost to follow-up;And there were 28 deaths and 6 survivors.Kaplan-Meier survival analysis showed no significant difference in survival rates between the two groups(P>0.05).【Conclusion】Carituzumab monoclonal antibody combined with chemotherapy has better efficacy in the treatment of elderly patients with lung cancer,which improves patient immune function.And it is safe and reliable.
作者 郭宏果 刘军 程才 乔松 陆婉玲 GUO Hong-guo;LIU Jun;CHENG Cai(Department of Oncology and Hematology,Air Force 986 Hospital,Xi'an Shaanxi 710054)
出处 《医学临床研究》 CAS 2023年第7期1039-1042,共4页 Journal of Clinical Research
关键词 肺肿瘤 抗体 单克隆 治疗结果 无进展生存期 老年人 Lung Neoplasms Antibodies,Monoclonal Treatment Outcome Progression-Free Survival Aged
  • 相关文献

参考文献9

二级参考文献66

  • 1迟小伟,刘杰.胃癌患者B7-CD28共刺激通路的研究[J].临床检验杂志,2005,23(2):106-107. 被引量:6
  • 2胡斌春,黄丽华.分级护理制度实施中的问题与建议[J].中国实用护理杂志(中旬版),2006,22(1):57-58. 被引量:59
  • 3金秀国,刘晓光,刘波,庄晓玲,方汉波,方国安.胃癌患者外周血淋巴细胞CD_8、CD_(28)表达的检测及临床意义[J].江西医学检验,2007,25(1):17-18. 被引量:11
  • 4刘晓光,金秀国,刘波,庄晓玲,方汉波,方国安.结肠癌患者外周血淋巴细胞CD_8和CD_(28)的表达[J].肿瘤学杂志,2007,13(1):68-69. 被引量:11
  • 5Emma J, Michaela DV, Denise G, et al. CD25-regulatory T cells and tumor immunity. Immunol Lett, 2003, 85(2): 141-143.
  • 6Rech AJ, Vonderheide RH. Chnical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann N YAcad Sci, 2009, 1174: 99-106.
  • 7Chu Y, Wang LX, Yang G, et al. Efficacy of GM-CSF-producing tumor vac- cine after docelaxel chemotherapy in mice bearing established Lewis lung carcinoma. J Immunother, 2006, 29(4): 367-380.
  • 8Filaci G, Fenoglio D, Fravega M, et al. CD8+CD28 T regulatory lymphocytes inhibiting T cell proliferative and cytotoxic functions infiltrate human can- cers.J Immunol, 2007, 179(7): 4323-4334.
  • 9Beyer M, Schultze JL. Regulatory T cells in cancer. Blood, 2006, 108(3): 804-811.
  • 10Ormandy LA, Hillemann T, Wedemeyer H, et al. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carci- noma. Cancer Res, 2005, 65(6): 2457-2464.

共引文献343

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部